Bayer UK launches new CanesMeno Educational Hub and product range to transform menopause support: Leverkusen Friday, January ...

However, Bayer's top-selling pharma product Xarelto (rivaroxaban), an anticoagulant, continued to succumb to generic competition with a near-11% fall to €904 million. The solid quarter is ...

Bayer pharma chief sees no big acquisitions in near ... of some long-running mass tort litigation based on traditional product liability theories of toxic exposure, and potentially the rise ...

Bayer recently submitted an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for this third indication for darolutamide in addition ...

Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...

“Rather than a lumbering corporation, Bayer will emerge as agile ... Another example: the company’s pharma division, based in Italy, has cut product release times by 50%.

Meanwhile, Bayer's Pharmaceutical division has delivered ... This growth was driven by significant gains from new products, with Nubeqa and Kerendia achieving growth rates of 83.2% and 96.4% ...

AB-1005 has received U.S. FDA Fast Track and UK Medicines and Healthcare products Regulatory Agency ... rigorous assessment and prioritization, Bayer Pharmaceuticals is now fully focused on ...

At the same time, the value of our pipeline is growing by accelerating breakthrough innovations," said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s ...